With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the month's most ...
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...
Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...
Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...
A group of Canadian undergrads is using plants to revolutionize medicine. Faced with soaring drug prices and global shortages ...
Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...
Contrave and Wegovy are both weight loss medications. Learn about their effectiveness, side effects, costs, and which ...
The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...
If you’re thinking about trying weight loss medication, you probably have a lot of questions about how it works, and how fast ...
As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.
Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback